Abstract
The “Wuhan Virus” was first recognized in the beginning of December 2019 and identified as a new type of coronavirus 2019-nCoV. This coronavirus-induced pneumonia originated from Wuhan (China), and has spread across 27 countries, infected 17,488 people and caused 362 deaths, at the this Editorial went to press. The transmission of 2019-nCoV to individuals of different countries is predominantly through close contact with an infected person. The experts around the global raise the concern on the rising number of infected cases and deaths, and increased the effort to produce an effective drug or vaccine for this virus. Several efforts have been done to aid the detection of the virus and treatment of patients: 2019-nCoV detection kits (BGI), and development of two new hospital, and treating patients with combination of antiviral for flu and HIV. In the United States, doctors successfully treated a 2019-nCoV patient with Gilead Sciences drug – remdesivir, however further test need to be done to confirm the effectiveness of these antivirals. Hopefully, the pharmaceutical companies with the team of researchers will be able to discover an effective vaccine to treat coronavirus 2019-nCoV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
